Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study

Kim, Namwoo; Kim, Jeewuan; Yang, Bo; Hahm, Bong‐Jin

doi:10.3344/kjp.2022.35.4.458

Cited by 4 publications

(3 citation statements)

References 31 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The electronic search identified a total of 2057 records; after title screening and duplicates removal, 260 articles were screened and finally 20 full-text articles were assessed for eligibility (Figure 1). Of the 20 records selected, five studies were excluded for reporting FD or IBS without using Rome criteria, [26][27][28][29][30] three for reporting FD or IBS rates without reporting COVID-19 diagnosis, [31][32][33] one for reporting FD and IBS in children 34 and one for inability to extract number of subjects and/or number of events from cases. 35 Thus, a total of 10 studies, [12][13][14][36][37][38][39][40][41][42] all full texts, met the eligibility criteria and were included in the meta-analysis.…”

Section: Study Selectionmentioning

confidence: 99%

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Introduction The burden of post‐COVID‐19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta‐analysis was to estimate the rate of post‐COVID‐19 FD and IBS. Methods MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID‐19 survivors and controls (without COVID‐19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I2. Results Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID‐19 patients were considered for FD. Post‐COVID‐19 FD was reported by 72 patients (4%, 95% CI: 3%–5% and I2 0%). The pooled OR for FD development (three studies) in post‐COVID‐19 patients compared to controls was 8.07 (95% CI: 0.84–77.87, p = 0.071 and I2 = 67.9%). Overall, 10 studies including 2763 COVID‐19 patients were considered for IBS. Post‐COVID‐19 IBS was reported by 195 patients (12%, 95% CI: 8%–16%, I2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID‐19 patients compared to controls was 6.27 (95% CI: 0.88–44.76, p = 0.067 and I2 = 81.4%); considering only studies with a prospective COVID‐19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58–46.60, p < 0.001 and I2 = 0%). Conclusions COVID‐19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Forty-eight studies were excluded in the first screening because of duplication. After reading the titles, abstracts and full text of citations, 25 studies were excluded and 10 studies were included [16][17][18][19][20][21][22][23][24][25][26][27][28][29]. The PRISMA flow chart is shown in Fig.…”

Section: Study Selection and Baseline Characteristicsmentioning

confidence: 99%

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

Wang,

Zhou,

Huang

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder. Several studies have analyzed the long-term GI symptoms and IBS following coronavirus disease 2019 (COVID-19). The purpose of this study is to evaluate the incidence and predisposing factors for IBS following COVID-19 by a systematic review and meta-analysis. Methods: Electronic databases were searched to identify relevant studies. Primary outcomes were the pooled incidence rate of IBS following COVID-19 and the pooled relative risk (RR) for IBS in the COVID-19 group compared to the non-COVID-19 group. Secondary outcomes were the pooled RR and the standardized mean difference (SMD) for predisposing factors in the IBS group compared to the non-IBS group. Heterogeneity was evaluated using Cochran’s Q test and I 2 statistics. Results: Ten studies were included in this study. The pooled incidence rate of IBS in COVID-19 patients was 12%. The pooled incidence rate of IBS-D, IBS-C and IBS-M was 5%, 2% and 1%. The pooled incidence rate of IBS in 6 and 12 months was 10% and 3%. The pooled RR for IBS in COVID-19 patients was 1.23 [95% confidence interval (CI) = 0.50–3.01] compared to non-COVID-19 patients. The pooled RR or SMD for mild, moderate, and severe disease activity, procalcitonin (PCT), depression or anxiety in IBS patients following COVID-19 was 0.94 (95% CI = 0.74–1.21), 1.19 (95% CI = 0.65–2.21), 1.30 (95% CI = 0.63–2.66), 6.73 (95% CI = 6.08–7.38) and 3.21 (95% CI = 1.79–5.75). Conclusion: The incidence of IBS following COVID-19 was 12%. But it was not higher than the general population. We also found some predisposing factors for IBS including depression or anxiety, PCT.

show abstract

“…Headache is a frequent symptom during the acute phase of COVID-19 [ 7 , 8 ]. It occurs in around 47.1% of the patients [ 9 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

Persistent headache and chronic daily headache after COVID-19: a prospective cohort study

Carvalho,

Silva,

Rocha-Filho

2024

Korean J Pain

View full text Add to dashboard Cite

Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study

Cited by 4 publications

References 31 publications

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

Persistent headache and chronic daily headache after COVID-19: a prospective cohort study

Contact Info

Product

Resources

About